Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

ese trials served as the basis for the Company to initiate the large, registration-enabling Phase III trial designed under a special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA) of VELCADE and rituximab in patients with relapsed follicular lymphoma. The Company is on track to complete patient accrual in this Phase III trial in the first half of 2008, with final data expected in 2010. VELCADE is already approved by the FDA to treat relapsed mantle cell lymphoma (MCL). MCL is an aggressive, rapidly progressive subtype of NHL with median life expectancy for a patient with MCL, following first relapse, of one to two years.

About Non-Hodgkin's Lymphoma

NHL is the most common hematological cancer, the fifth leading cause of cancer death and the second fastest-growing form of cancer in the U.S. The prevalence of NHL in the U.S. is approximately 400,000 patients, including approximately 200,000 patients with diffuse large B-cell lymphoma, 100,000 patients with follicular and marginal zone lymphoma and 10,000 with MCL. There are approximately 54,000 new cases of NHL diagnosed in the U.S. per year, and 19,000 deaths are attributed to the disease annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co- promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the tre
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Wis. , July 30, 2014 ... developer, and marketer of over-the-counter (OTC) medicinal and ... the LipiGesic ® M name along with the ... be replaced with the trademarked name MigraPure ® ... color palette of PuraMed,s homeopathic, natural migraine pain ...
(Date:7/30/2014)... , July 30, 2014 Research and Markets ... Market - Forecasts to 2019" report to their offering. ... is estimated to grow at a lower CAGR in developed countries; ... such as China , India ... years. The growth of the hematology analyzers and reagents ...
(Date:7/30/2014)... RATON, Fla. , July 30, 2014  Today the ... for indoor and outdoor sun tanning or sun burns stating ... his statement Surgeon, General Boris Lushniak , says that ... skin types and that too much exposure to indoor and ... Center for Dermatology and Aesthetic Medicine, in Boca ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Hematology Analyzers & Reagents Market - Forecasts to 2019 2Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2
... SAN DIEGO, Dec. 18 Ambrx Inc. today ... collaboration with Merck & Co. Inc. to,develop a ... Growth Factor 21 (FGF-21) for the treatment of ... obesity., The collaboration utilizes Ambrx,s proprietary protein ...
... Reported in Q1 2008, PALO ALTO, Calif., ... ) announced today that it has completed,its target ... with AZ-104 (Staccato(R) loxapine) in patients with migraine,headache. ... which is being,developed to treat acute agitation in ...
Cached Medicine Technology:Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc. 2Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients 2Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients 3Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients 4
(Date:7/30/2014)... The report "Peracetic Acid Market by ... Food, Water Treatment, Pulp & Paper, & Others), by ... Trends & Forecasts to 2018". Peracetic Acid Market is ... by 2019, signifying a robust growth rate of over ... market data tables and 33 figures spread through 221 ...
(Date:7/30/2014)... who were breastfed for three months or more ... chronic inflammation associated with cardiovascular and metabolic diseases, ... Washington University in St. Louis. , "This study ... for children,s health decades later," said Molly W. ... and a co-author of the study with Thomas ...
(Date:7/30/2014)... San Ramon, CA (PRWEB) July 30, 2014 ... in the ancient redwood forests of the Pomo Indians ... California. The Pomo called the river Shabaikai, meaning ‘crooked ... with its labor strife and the violence of prohibition ... Bohemian Club at Russian River. Here, the most powerful ...
(Date:7/30/2014)... 2014 The Dr. Hector P. Garcia ... announced the proposed naming of the new primary care ... Garcia Family Health Center. , The proposed 40,000 sq. ... including comprehensive chronic disease management programs, pharmacy services and ... pioneering medical home model center. , Dr. Hector P. ...
(Date:7/30/2014)... 30, 2014 Naomi Fried, PhD, ... Board of Directors of the American Telemedicine Association ... Association, which has a mission to promote professional, ... telecommunications and information technology. , “Both Naomi Fried ... possess extraordinary expertise and are well known experts ...
Breaking Medicine News(10 mins):Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2
... July 27 Childhood obesity causes lifelong illness, leads to ... premature death in adulthood due to medical conditions such as ... human toll, childhood obesity alone costs the nation,s health care ... To address the continued tide of obesity in children, Highmark ...
... , , MINNEAPOLIS and ST. ... recently designated Children,s Hospitals and Clinics of Minnesota,s two hospital ... has the sixth busiest pediatric emergency department in the nation ... 450 trauma cases each year. Children,s voluntarily participated in ...
... healthy behaviors will bring expenditures down, experts say , , ... States now carries the hefty price tag of $147 billion ... of all medical spending, experts report. , In fact, people ... health care -- about 41 percent more than an average-weight ...
... , , , , ... leading pharmacy automation provider, today announced the pharmacy industry,s first and ... fulfills the long-unmet need for a system that handles all the ... a fraction of the cost. , , The KL60 ...
... , , Study explores $187.1 million ... to 193 members of Congress on ... care bills , , , Members of ... up have received significantly more than their ...
... ... the field of medical implants will keynote the upcoming Materials and Processes for Medical ... ... the field of medical implants will keynote the upcoming Materials and Processes for Medical ...
Cached Medicine News:Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Children's Hospitals and Clinics of Minnesota Receive Level III Trauma Designation 2Health News:Children's Hospitals and Clinics of Minnesota Receive Level III Trauma Designation 3Health News:Almost 10 Percent of U.S. Medical Costs Tied to Obesity 2Health News:Almost 10 Percent of U.S. Medical Costs Tied to Obesity 3Health News:Kirby Lester's New KL60: The Pharmacy Industry's First and Only Compact, Fully-Automated Dispensing System 2Health News:Elected Officials Voting Against Health Reform Received 65% More in Campaign Donations From Health and Insurance Interests Than Those Voting for Reform 2Health News:Elected Officials Voting Against Health Reform Received 65% More in Campaign Donations From Health and Insurance Interests Than Those Voting for Reform 3Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2
Disposable tracheostomy care tray....
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
Medicine Products: